Eli Lilly returns to Indianapolis from San Jose as trade war with Germany escalates

Eli Lilly’s Gulfstream G500, tail N307EL, landed at Indianapolis International Airport at 7:00 p.m. local time on June 19 after a three-hour, 23-minute flight from San Jose, California. The company’s return to its headquarters coincided with the same week the U.S. government formally opened a Section 301 investigation into Germany’s pharmaceutical pricing policies, a probe that followed Lilly’s decision to halve a planned €2.3 billion investment in its Alzey manufacturing site [dw.com](https://www.dw.com/en/us-probes-germanys-persistent-underpayment-for-drugs/a-77620250).

The same week, Lilly’s CEO Dave Ricks was likely in the Bay Area meeting with telehealth partners that have been central to the launch of Foundayo, the company’s first FDA-approved oral GLP-1 pill. As of late April, more than a dozen telehealth firms accounted for roughly 35% of Foundayo’s initial prescription volume, according to a Reuters report [srnnews.com](https://srnnews.com/eli-lilly-raises-annual-profit-forecast-on-sustained-weight-loss-drug-demand/). The San Jose flight suggests the company is pressing that distribution strategy just as pricing pressures mount at home and abroad.

Lilly’s recent flight pattern shows a heavy concentration of trips to the Northeast and Florida, with the San Jose visit as an outlier. The company has been under investor scrutiny to sustain growth amid lower realized prices on Mounjaro and Zepbound, pressure that the new trade investigation may only intensify.